Suppr超能文献

连续波与微脉冲经巩膜睫状体光凝术治疗效果的比较:一项回顾性队列研究。

Comparison of outcomes of continuous-wave and micropulse trans-scleral cyclophotocoagulation: A retrospective cohort study.

作者信息

Hallaj Shahin, Pashaee Bahram, Nieves Christian J, Shah Sagar J, Ezeonu Sopuruchukwu, Xia Tina, Garg Ananya, Sheng Young, Dale Elizabeth A, Schmidt Courtland, Shukla Aakriti G, Pro Michael J, Kolomeyer Natasha N, Lee Daniel, Moster Marlene R, Myers Jonathan S, Razeghinejad Reza

机构信息

Glaucoma Service, Wills Eye Hospital, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.

Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, CA, USA.

出版信息

Eur J Ophthalmol. 2025 Sep;35(5):1647-1653. doi: 10.1177/11206721251332674. Epub 2025 Apr 15.

Abstract

PurposeThis study aimed to compare and provide data on the outcomes of continuous wave (CWCPC) and micropulse transscleral cyclophotocoagulation (MPCPC).MethodsThis was a retrospective cohort study of 130 glaucomatous eyes that underwent CWCPC with a minimum 6-month follow-up matched 1:1 with 130 eyes that underwent MPCPC. The main outcome measure was CPC failure, defined as intraocular pressure (IOP) reduction of <20%, therapy advancement, or progression to no light perception. The secondary outcome measure was safety profile and complications.ResultsThe mean age of patients in the CWCPC and MPCPC groups was 64.4 ± 16.4 and 64.0 ± 17.2 years, respectively. Most patients were male (56.5%), and 48.5% were White. Primary open-angle glaucoma was the most common glaucoma diagnosis (40.4%), 58.5% of the patients had severe glaucoma. Mean preoperative IOP and number of medications were 29.8 ± 10.6 mmHg and 3.7 ± 1.3, respectively. The failure rates at 6 months (46.9% vs. 18.5%) and 1 year (61.5% vs. 40.8%) were higher in MPCPC group ( = 0.001). Mean IOP reduction was slightly greater in the CWCPC group (15.1 ± 13.9 mmHg vs. 14.2 ± 10.4,  = 0.5). Lower laser energy (HR:0.995) and MPCPC (HR:1.698) were associated with higher risk of failure ( = 0.002). The complication rate was higher in the CWCPC group (13.8% vs. 4.6%,  < 0.001); vision loss occurred more in the CWCPC group (4.6% vs. 2.3%), and the only phthisis bulbi occurred in one of the eyes of CWCPC group.ConclusionCWCPC was more effective in lowering the IOP despite delivering less total energy than MPCPC but had a higher rate of complications.

摘要

目的

本研究旨在比较连续波经巩膜睫状体光凝术(CWCPC)和微脉冲经巩膜睫状体光凝术(MPCPC)的治疗效果并提供相关数据。

方法

这是一项回顾性队列研究,对130只接受CWCPC且随访至少6个月的青光眼患眼进行研究,将其与130只接受MPCPC的患眼按1:1匹配。主要观察指标为睫状体光凝术失败,定义为眼压(IOP)降低<20%、治疗进展或进展至无光感。次要观察指标为安全性和并发症。

结果

CWCPC组和MPCPC组患者的平均年龄分别为64.4±16.4岁和64.0±17.2岁。大多数患者为男性(56.5%),48.5%为白人。原发性开角型青光眼是最常见的青光眼诊断类型(40.4%),58.5%的患者患有严重青光眼。术前平均眼压和用药数量分别为29.8±10.6 mmHg和3.7±1.3。MPCPC组6个月(46.9%对18.5%)和1年(61.5%对40.8%)的失败率更高(P = 0.001)。CWCPC组平均眼压降低幅度略大(15.1±13.9 mmHg对14.2±10.4,P = 0.5)。较低的激光能量(HR:0.995)和MPCPC(HR:1.698)与更高的失败风险相关(P = 0.002)。CWCPC组的并发症发生率更高(13.8%对4.6%,P<0.001);CWCPC组视力丧失更多(4.6%对2.3%),唯一的眼球痨发生在CWCPC组的一只患眼中。

结论

尽管CWCPC输送的总能量低于MPCPC,但其在降低眼压方面更有效,但并发症发生率更高。

相似文献

1
Comparison of outcomes of continuous-wave and micropulse trans-scleral cyclophotocoagulation: A retrospective cohort study.
Eur J Ophthalmol. 2025 Sep;35(5):1647-1653. doi: 10.1177/11206721251332674. Epub 2025 Apr 15.
2
Continuous wave transscleral cyclophotocoagulation with the slow-cooking protocol to treat refractory glaucomas.
Eur J Ophthalmol. 2025 Sep;35(5):1654-1665. doi: 10.1177/11206721251335381. Epub 2025 Apr 21.
3
Cyclodestructive procedures for non-refractory glaucoma.
Cochrane Database Syst Rev. 2018 Apr 25;4(4):CD009313. doi: 10.1002/14651858.CD009313.pub2.
4
Safety and efficacy of micropulse transscleral cyclophotocoagulation: 2-year follow-up in a tertiary Canadian centre.
Can J Ophthalmol. 2024 Feb;59(1):19-23. doi: 10.1016/j.jcjo.2022.10.012. Epub 2022 Nov 8.
5
6
Long-Term Results of Transscleral Diode Laser Cyclophotocoagulation in Glaucoma: A Real-Life Study.
J Glaucoma. 2024 Jun 1;33(6):437-443. doi: 10.1097/IJG.0000000000002346. Epub 2023 Dec 21.
8
Safety and efficacy of MicroPulse transscleral laser therapy with the revised P3 delivery device: A randomized controlled trial.
Eur J Ophthalmol. 2025 Sep;35(5):1863-1874. doi: 10.1177/11206721251340102. Epub 2025 May 8.
10
Continuous Wave Transscleral Cyclophotocoagulation and Endoscopic Cyclophotocoagulation in Childhood Glaucoma: A Meta-Analysis.
J Glaucoma. 2024 Jun 1;33(6):456-463. doi: 10.1097/IJG.0000000000002365. Epub 2024 Jan 26.

本文引用的文献

2
Micropulse vs. continuous wave transscleral cyclophotocoagulation in neovascular glaucoma.
Exp Ther Med. 2022 Apr;23(4):278. doi: 10.3892/etm.2022.11207. Epub 2022 Feb 11.
3
Micropulse Transscleral Cyclophotocoagulation.
J Curr Glaucoma Pract. 2021 Jan-Apr;15(1):1-7. doi: 10.5005/jp-journals-10078-1298.
4
Efficacy, Safety, and Retreatment Benefit of Micropulse Transscleral Cyclophotocoagulation in Glaucoma.
J Glaucoma. 2021 Sep 1;30(9):781-788. doi: 10.1097/IJG.0000000000001900.
5
Efficacy and Safety of Repeated Micropulse Transscleral Diode Cyclophotocoagulation in Advanced Glaucoma.
J Glaucoma. 2021 Jul 1;30(7):566-574. doi: 10.1097/IJG.0000000000001862.
6
Treatment Outcomes of Primary Transscleral Cyclophotocoagulation.
Ophthalmol Glaucoma. 2021 Sep-Oct;4(5):472-481. doi: 10.1016/j.ogla.2020.12.014. Epub 2021 Jan 8.
7
Histologic effects of MicroPulse™ transscleral cyclophotocoagulation in normal equine eyes.
Vet Ophthalmol. 2021 Jan;24(1):59-70. doi: 10.1111/vop.12846. Epub 2020 Nov 29.
9
A Review of Cyclodestructive Procedures for the Treatment of Glaucoma.
Semin Ophthalmol. 2020 Aug 17;35(5-6):261-275. doi: 10.1080/08820538.2020.1810711. Epub 2020 Sep 16.
10
Histologic Changes Following Continuous Wave and Micropulse Transscleral Cyclophotocoagulation: A Randomized Comparative Study.
Transl Vis Sci Technol. 2020 Apr 28;9(5):22. doi: 10.1167/tvst.9.5.22. eCollection 2020 Apr.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验